血液和尿液中草甘膦的净化富集及检测

目的建立血液、尿液中草甘膦的净化富集及定性定量方法。方法取适量血、尿样品,用80%甲醇水溶液稀释,经Agilent Accu Bond NH2（弱阴离子交换柱）净化富集,用3m L 5%氨水溶液洗脱后进行ESI/LC/MRM对草甘膦的定性及阴离子色谱法（IC）的定量检验分析。结果血液、尿液中草甘膦的IC法检验回收率均大于90%,方法的线性范围均在1-100μg/m L,血检测限为0.1μg/m L,尿液为0.08μg/m L。血液、尿液中草甘膦的LC/MRM的方法检测限均在5ng/m L左右。结论建立的血、尿中草甘膦的前处理方法和LC/MRM定性分析及IC定量分析方法,可满足司法检验要求。     

测定单根毛发中吗啡含量的放射免疫方法

目的 建立测定单根毛发中吗啡含量的放免方法。方法 用卵清蛋白-琥珀酰吗啡作免疫原,免疫新西兰白兔获得高品质抗血清;HPLC纯化~(125)Ⅰ-吗啡,建立放射免疫方法,测定正常人和吸毒人员单根毛发。结果 抗体亲和常数为3.25×10~(11)L/M,放化纯度为95％,比放射性112μCi/μg;方法的灵敏度为0.01ng/ml。对5例正常人及5例戒毒所吸毒人员的单根毛发进行了检测。单根毛发长度9～24cm,重量为0.7～2.1mg,5例正常人测值为1.75±0.37ng/mg(x±s);5例吸毒人员测值为471±204ng/mg(x±s)。结论 所建方法可准确定量单根毛发中吗啡的含量。     

腐败生物检材中多种碱性滥用药物的检测

目的建立腐败生物检材中多种碱性滥用药物的提取、净化和仪器分析方法。方法用环己烷作为提取溶剂液-液萃取,同时采用Bond Elut Certify小柱、甲醇淋洗、二氯甲烷:异丙醇:氨水(78:20:2)洗脱固相萃取分离提取,GC/MS、GC/NPD定性定量分析各种生物检材中的滥用药物。结果从所送死者肝组织、胃组织、心血及胃内容、尿样、各检材中均同时检出吗啡、可待因、舒乐安定和异丙嗪成份,其中肝组织含量分别为吗啡0.094μg/g、可待因0.257μg/g、异丙嗪0.110μg/g,尿液含量分别为吗啡0.334μg/ml、可待因4.054μg/ml、异丙嗪0.066μg/ml,心血含量分别为吗啡0.036μg/ml、可待因0.106μg/g、异丙嗪0.088μg/ml。结论此方法准确、可靠、科学,可以用于法医毒物分析领域体内检材多种碱性药物的检测。     

氯胺酮胶体金标记单克隆抗体免疫层析检测板的研制

目的建立一种简便快速检测氯胺酮的方法。方法将20nm胶体金颗粒标记的抗氯胺酮单克隆抗体,均匀浸在吸水玻璃纤维上,用点膜机将氯胺酮-BSA和纯化后的羊抗鼠IgG多克隆抗体在硝酸纤维薄膜分别划1mm宽的检测线(T线)和质控线(C线),然后依次将吸水玻璃纤维、硝酸纤维薄膜和吸水滤纸粘贴于白色的塑料片上,切成0.5 cm×10 cm大小,制成氯胺酮胶体金标记单克隆抗体免疫层析检测条,并组装成检测板,并检测其特异性和灵敏度。结果氯胺酮胶体金标记单克隆抗体免疫层析检测板在对46种药(毒)物的测试中,仅识别氯胺酮及其主要代谢产物,其准确性为97.6%,检测氯胺酮的阈值为1000ng/m l。结论氯胺酮胶体金标记单克隆抗体免疫层析检测板在5m in内可检出样品中的氯胺酮及其代谢物。     

UPLC-MS/MS分析尿液中阿片类化合物

目的 建立尿液中同时分析可待因(codeine,COD)、6-单乙酰吗啡(6-monoacetylmorphine,6-MAM)、吗啡(morphine,MOR)、吗啡-3-葡萄糖醛酸苷(morphine-3-glucuronide,M3G)和吗啡-6-葡萄糖醛酸苷(morphine-6-glucuronide,M6G)的超高效液相色谱-串联质谱(UPLC-MS/MS)方法.方法 以吗啡-d3(MOR-d3)和吗啡-3-葡萄糖醛酸苷-d3(M3G-d3)为内标,尿液用乙腈沉淀蛋白后,过SiroccoTM蛋白沉淀板,UPLC-MS/MS法分离检测.结果 尿液中COD和MAM检出限为0.2 ng/Ml,定量限为0.5 ng/Ml;MOR、M3G和M6G检出限为0.5 ng/Ml,定量限为1 ng/Ml;线性相关系数r≥0.999 7;日内精密度和日间精密度均在10%以内;回收率70.0%～98.3%,基质效应50.5%～99.0%.结论 所建方法简便、快速、准确,可以满足法庭毒物分析的需要.     

生物检材中吗啡类生物碱的LC-MS／MS分析

目的针对滥用药物分析鉴定实践中亟待解决的问题,开展LC-MS/MS分析生物检材中吗啡类生物碱的应用研究。方法满足不同的鉴定需要,分别建立血液、尿液、唾液和头发等生物检材的样品前处理方法,确定同时分析海洛因、单乙酰吗啡、吗啡、可待因、乙酰可待因、二氢可待因酮和氢吗啡酮等吗啡类生物碱的LC-MS/MS方法。将方法应用于实际案例。结果所建立的方法对吗啡类生物碱分离良好。尿液稀释法、尿液提取法和头发中吗啡的最低检测限(LOD)分别为10ng/mL、0.01ng/mL和0.01ng/mg。结论所建立的方法简便、快速、特异性强、灵敏度高。目标物中加入二氢可待因酮和氢吗啡酮扩大了方法的实用范围。     

UPLC-MS/MS测定唾液中的3种毒品成分

目的建立了超高效液相色谱-串联质谱法同时检测唾液中的甲基苯丙胺、氯胺酮和吗啡成分。方法唾液样品经沉淀蛋白后,通过ACQUITY UPLC BEH Phenyl(100mm×2.1mm,1.7μm)色谱柱分离,以0.3%甲酸水和乙腈作为流动相进行梯度洗脱,采用电喷雾离子源正离子(ESI+)多反应监测(MRM)模式进行质谱分析。结果甲基苯丙胺、氯胺酮和吗啡在4μg/L^20μg/L质量浓度范围内线性关系良好;在4μg/L、10μg/L、50μg/L、100μg/L、200μg/L五组添加样本下,添加回收率范围在87%~128%;甲基苯丙胺、氯胺酮、吗啡的检出限(LOD)和定量限(LOQ)均分别为0.2μg/L和4μg/L。结论本方法采用乙腈沉淀蛋白提取,快速、简单、回收率高,适用于同时检测唾液中甲基苯丙胺、氯胺酮和吗啡。     

LC-MS/MS法同时检测生物检材中钩吻素子、钩吻素甲和钩吻素己CSCD

目的建立准确、灵敏的生物检材中钩吻素子、钩吻素甲及钩吻素己的液相色谱-串联质谱(LCMS/MS)检测方法,并进行方法学验证。方法以士的宁为内标,血液、尿液及肝组织样品经1%氢氧化钠溶液碱化后用乙酸乙酯提取,采用ZORBAX SB-C_(18)柱(150 mm×2.1 mm,5μm)分离,以甲醇-20 mmol/L乙酸铵缓冲溶液(含0.1%甲酸和5%乙腈)为流动相进行梯度洗脱。定性定量分析采用电喷雾正离子化(ESI+)、多反应监测模式。结果血液、尿液及肝组织中钩吻素子、钩吻素甲和钩吻素己在相应的线性范围内线性良好,相关系数(r)>0.995 0,检出限分别为0.1 ng/m L(或0.1 ng/g)、0.1 ng/m L(或0.1 ng/g)及0.01 ng/m L(或0.01 ng/g),各生物碱提取回收率为61.9%~114.6%,准确度为92.4%~114.3%,日内、日间精密度的相对标准偏差均不超过11.0%。结论本方法选择性好、灵敏度高,适用于同时检测生物体液和组织中的钩吻素子、钩吻素甲和钩吻素己,可为钩吻中毒的临床诊治和法医学鉴定提供有效的技术支撑。     

1,8-二氨基萘衍生化GC/MS法测定尿中的亚硝酸盐含量

目的建立快速准确测定尿液中的亚硝酸盐含量的方法。方法采用1,8-二氨基萘(1,8-DAN)衍生化气相色谱-质谱(GC/MS)法进行分析,并对实验参数如p H值、衍生化温度和时间进行了优化。结果本方法测定尿液中的亚硝酸盐含量的线性范围0.01~20μg/m L,相关系数R~2=0.998 4,检测限为0.005μg/m L,日内精密度(n=4)为3.49%~4.31%;日间精密度(n=5)为4.18%~5.76%,回收率为88.37%~116.0%,实验耗时30min。结论该方法可直接在尿液中进行衍生化GC/MS分析,具有耗时更短、检测限更低、回收率和精密度高的优点,操作简便快捷,在法医毒物分析中具有实际应用价值。     

氯胺酮、甲基苯丙胺和吗啡金标单抗试剂盒的研制

目的建立同步检测氯胺酮、甲基苯丙胺和吗啡的方法。方法将胶体金标记的抗氯胺酮、抗甲基苯丙胺和抗吗啡单克隆抗体浸涂在玻璃纤维膜上，将氯胺酮、甲基苯丙胺和吗啡的完全抗原以及羊抗鼠多克隆抗体喷涂在硝酸纤维素膜上，分别标定为检测区（T）和质控区（C）。样本中游离的氯胺酮、甲基苯丙胺和吗啡分别与包被的完全抗原免疫竞争结合胶体金标记抗氯胺酮、抗甲基苯丙胺和抗吗啡单克隆抗体。以质控区和检测区是否出现紫红色条带判读结果。结果对66种药品和毒品的特异性测试表明，该试剂盒仅识别氯胺酮及其代谢物、甲基苯丙胺及其衍生物和吗啡类；对人体尿样中的氯胺酮、甲基苯丙胺和吗啡检测阈值分别为1000ng／ml、1000ng／ml和300ng／ml；与GC／MS对照试验结果一致；试剂盒稳定性较好，在常温下可较长时间保存。结论本文研制的试剂盒可用于样本中氯胺酮、甲基苯丙胺和吗啡成分定性的同步检测。     

The detection of acetylcodeine and 6-acetylmorphine in opiate positive urines

Acetylcodeine (AC), an impurity of illicit heroin synthesis, was investigated as a urinary biomarker for detection of illicit heroin use. One hundred criminal justice urine specimens that had been confirmed positive by GC/MS for morphine at concentrations >5000 ng/ml were analyzed for AC, 6-acetylmorphine (6AM), codeine, norcodeine and morphine. The GC/MS analysis was performed by solid phase extraction and derivatization with propionic anhydride. Total codeine and morphine concentrations were determined by acid hydrolysis and liquid/liquid extraction. AC was detected in 37 samples at concentrations ranging from 2 to 290 ng/ml (median, 11 ng/ml). 6AM was also present in these samples at concentrations ranging from 49 to 12 600 ng/ml (median, 740 ng/ml). Of the 63 specimens negative for AC, 36 were positive for 6AM at concentrations ranging from 12 to 4600 ng/ml (median, 124 ng/ml). When detected, the AC concentrations were an average of 2.2% (0.25 to 10.2%) of the 6AM concentrations. There was a positive relationship between AC concentrations and 6AM concentrations (r=0.878). Due to its very low concentration in urine, AC was found to be a much less reliable biomarker for illicit heroin use than 6AM in workplace or criminal justice urine screening programs. However, AC detection could play an important role in determining if addicts in heroin maintenance programs are supplementing their supervised diacetylmorphine doses with illicit heroin.     

胶体金标记检测大麻单克隆抗体免疫试剂盒研制

目的 建立准确、快速、简便的检测尿液中大麻的胶体金免疫层析技术(ICT)。方法 采用柠檬酸三钠还原法制备胶体金颗粒,标记抗主要代谢物四氢大麻酚-9-羧酸,THC与GC/MS检测方法相比,用ICT法的216份尿样,其检测限为50 ng/ml,灵敏度为96.67％,准确性为98.61％。结论 ICT法检测尿液中THC,其特异性强,对确定大麻的存在具有广泛的应用价值。     

Enzyme-linked immunosorbent assay and latex agglutination inhibition reaction test for cocaine and benzoylecgonine in urine

An enzyme-linked immunosorbent assay (ELISA) and a latex agglutination inhibition reaction test (LAIRT) for cocaine and benzoylecgonine have been established. In ELISA with polystyrene microtiter wells coated with anti-benzoylecgonine antibody and alkaline phosphatase (ALP)-labeled benzoylecgonine, the activity of antibody-bound ALP was measured with the enzyme cycling method. The range of benzoylecgonine measurable by ELISA was 12 pg-25 ng/well; the analysis time for 96 wells was 90 min. In LAIRT, the agglutination reaction with anti-benzoylecgonine antibody-coated latex and benzoylecgonine-rabbit serum albumin (RSA) conjugate-coated latex was inhibited by 0.1 μg benzoylecgonine/ml urine; the analysis time for six samples on one glass slide was 20 min. The urine samples of 47 abusers were analyzed by ELISA and LAIRT. From the comparison with results of the enzyme-multiplied immunoassay technique (EMIT^®) and gas chromatography-mass spectrometry (GC-MS), it was clarified that both ELISA and LAIRT were suitable for the screening method of urine samples.     

Development of an Antibody Hapten‐Chip System for Detecting the Residues of Multiple Antibiotic Drugs*

Abstract: The abuse of antibiotic drugs during animal production remains a worldwide problem and the subsequent detection of the residues of various drugs present at low concentrations in complex biological matrices poses significant analytical challenges. The present study outlines a practical biochip assay system to identify antibiotic residues in different animal tissue extracts. The system uses a simple but efficient multiresidue sample extraction procedure to isolate the antibiotic residues which were then identified directly using high‐affinity monoclonal antibodies presented in a competitive immunoassay with conjugated antibiotic hapten‐chips. The hapten‐chip can analyze six samples each for eight antibiotics on a single chip within 3 h. The analytical results with both artificial positive standard samples and the incurred samples show that the antibody hapten‐chip system has a comparable accuracy and a similar sensitivity to a standard ultra performance liquid chromatography–mass spectrometry (MS)/MS assay. In conclusion, an effective analytical screening system based on antibody hapten‐chip was developed for detecting multiple antibiotic residues from multiple samples.     

尿样中海洛因代谢物的测定及海洛因滥用的确认

用ＳＰＥ－ＧＣ－ＮＰＤ法建立了尿样中吗啡、６－单乙酰吗啡及可待因的定性分析方法,适用于海洛因滥用者的尿样分析。尿样中吗啡及可待因的最小检测限均为５０ｎｇ／ｍｌ。方法的相对标准偏差分别为：吗啡１１．３％（ｎ＝５）,可待因１４．２％（ｎ＝５）。方法简便、灵敏、快速,１５ｍｉｎ可完成一例尿样的分析。研究了服用含可待因成分的复方甘草合剂后,尿样中的吗啡及可待因的峰面积比为０．４５７±０．１９７（Ｐ＝９９％）;统计了４０例明确滥用海洛因尿液的分析结果,吗啡与可待因的峰面积比为３．４６±０．８９４,Ｐ＝９９％。可作为判断海洛因滥用的依据。同时与免疫板法比较,附５５例免疫板法阳性尿样的分析结果     

抗丁丙诺啡单克隆抗体的制备

目的建立抗丁丙诺啡单克隆抗体的杂交瘤细胞株，制备高特异性的丁丙诺啡单克隆抗体，并对其免疫学特性进行鉴定。方法在丁丙诺啡的分子上连接活性羧基基团，通过缩合反应将丁丙诺啡半抗原连接于血蓝蛋白（KLH）和小牛血清白蛋白（BSA），形成完全抗原。以完全抗原免疫Balb／c小鼠，通过细胞融合，筛选等杂交瘤技术，建立稳定的分泌抗丁丙诺啡单克隆抗体的杂交瘤细胞株。通过腹腔注射杂交瘤细胞，诱导小鼠产生含有单抗的腹水。用辛酸-硫酸铵加亲和层析法纯化抗丁丙诺啡单克隆抗体。采用酶联免疫反应和胶体金膜层析实验测定丁丙诺啡单抗的特异性以及免疫反应动力学参数。结果共获得3株分泌抗丁丙诺啡单克隆抗体的杂交瘤细胞株，分别命名为7E6，6G4和3C2。7E6，6G4抗体灵敏度为10．0ng／ml，3C2抗体灵敏度为20．0ng／ml。7E6，6CA和3C2抗体的亲和常数分别为3．6×10^-9 mol／L，4．3×10^-9 mol／L和6．3×10^-9 mol／L。特异性测试结果表明7E6和6G4抗体与40种药物、毒品无任何交叉反应，而3C2抗体与吗啡有交叉反应。结论杂交瘤细胞株7E6和6G4产生的抗丁丙诺啡单克隆抗体具有很高的特异性和灵敏度。     

柱切换HPLC法分析尿中吗啡和O^6—单乙酰吗啡的研究

目的建立用柱切换HPLC技术分析尿中吗啡和06-单乙酰吗啡的方法.方法尿样用硼砂缓冲液(pH9.2)稀释后进入预处理柱(YWG-C18,33mm×5.0mm,10μm),用H2O洗去杂质,再用CH3OHH2O(6040)将被分析组分洗脱进入分析柱(Lichrospher(R)100CN,125mm×4.0mm,5μm),分析流动相为CH3OH磷酸盐缓冲液(pH6.86)=2278.紫外检测器波长为286nm.结果尿中吗啡和06--单乙酰吗啡的线性范围分别为50～1 600n/ml和100～1 600n/ml.吗啡和O6--单乙酰吗啡的精密度均小于4%.吗啡和O6-单乙酰吗啡的检测限均为40n/ml.结论用CSHPLC测定尿中吗啡和O6-单乙酰吗啡,方法准确、灵敏、快速、简便.     

胶体金标记苯丙胺单克隆抗体免疫试剂盒研究

目的建立一种准确、快速、简便的检测尿液中苯丙胺(AMP)的胶体金免疫层析技术。方法采用柠檬酸三钠还原法制备胶体金颗粒,标记抗AMP单抗,将AMP—BSA抗原固相于硝酸纤维素膜上,制备胶体金免疫层析测试条。通过尿液、血液和唾液中的可能存在的苯丙胺成分与测试条上的苯丙胺-BSA完全抗原竞争结合有限的单抗结合位点,来判定检测结果。结果用ICT法和GC/MS检测217份尿样,本法检测阈值为1000ng/mL,特异性为99.17%,准确性为99.54%。结论ICT法检测尿液中的AMP特异性强,灵敏度高、简便快速、无需特殊仪器设备,具有广泛应用价值。     

Time of drug elimination in chronic drug abusers. Case study of 52 patients in a "low-step" detoxification ward

The elimination time of illicit drugs and their metabolites is of both clinical and forensic interest. In order to determine the elimination time for various drugs and their metabolites we recruited 52 volunteers in a protected, low-step detoxification program. Blood samples were taken from each volunteer for the first 7 days, daily, urine sample for the first 3 weeks, daily. Urine was analyzed using a fluorescence-polarization immunoassay (FPIA) and gas chromatography/mass spectrometry (GC/MS), serum using GC/MS. The elimination times of the drugs and/or their metabolites in urine and serum as well as the tolerance intervals/confidence intervals were determined. Due to the sometimes extremely high initial concentrations and low cut-off values, a few of the volunteers had markedly longer elimination times than those described in the literature. The cut-off values were as follows: barbiturates II (200ng/ml), cannabinoids (20ng/ml), cocaine metabolites (300ng/ml), opiates (200ng/ml). GC/MS detected the following maximum elimination times: total morphine in urine up to 270.3h, total morphine and free morphine in serum up to 121.3h, monoacetylmorphine in urine up to 34.5h, 11-nor-9-carboxy-delta-9-tetrahydrocannabinol (THC-COOH) in urine up to 433.5h, THC-COOH in serum up to 74.3h, total codeine in urine up to 123h, free codeine in urine up to 97.5h, total codeine in serum up to 29h, free codeine in serum up to 6.3h, total dihydrocodeine (DHC) in urine up to 314.8h, free DHC in urine up to 273.3h, total and free DHC in serum up to 50.1h. Cocaine and its metabolites were largely undetectable in the present study.